(b) the PLGA polymer has a ratio of lactide to glycolide ranging from [in the polymer is] from about 100:0 to 50:50 weight percent;

(c) the [inherent viscosity of] PLGA polymer has an inherent viscosity of [polymers used in the microspheres is] about 0.1 to 1.2 dL/g;

(d) the microspheres have a median diameter ranging [of the microspheres is] from about 20 to 100 μm; and

B' cont.

(e) the microspheres have an antigen release profile [antigen is released from the microspheres in a triphasic pattern] characterized by three phases: a first phase, wherein about 0.5 to 30 percent of the antigen is released from the microspheres over a period of about 1 to 2 days [day], a second phase [,] beginning at the completion of the first phase wherein less than 10 percent of the antigen is released from the microspheres over a period ranging from [of between] about 30 to 180 days, and a third phase beginning at the completion of the second phase wherein the remaining antigen is released from the microspheres over a period ranging from [of] about 10 to 30 days.

B2

6. (Amended) The composition of claim 5 wherein the adjuvant is encapsulated in [the PLGA] microspheres.

23. (Amended) The composition according to claim 1 wherein antigen release occurs in the second phase [is] over a period of about 30 days.

24. (Amended) The composition according to claim 1 wherein antigen release occurs in the second phase [is] over a period of about 60 days.

B3

25. (Amended) The composition according to claim 1 wherein antigen release occurs in the second phase [is] over a period of about 90 days.

26. (Amended) The composition according to claim 1 wherein antigen release occurs in the second phase [is] over a period of about 120 days.